EMEA-002817-PIP04-20 - paediatric investigation plan

Faricimab

Key facts

• Active Substance:
  Faricimab
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/0333/2020
• PIP number:
  EMEA-002817-PIP04-20
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of retinal vein occlusion
• Route(s) of administration:
  Intravitreal use
• Contact for public enquiries:

  Roche Registration GmbH

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  28/08/2020

Decision

P/0333/2020 : EMA decision of 28 August 2020 on the granting of a product specific waiver for faricimab (EMEA-002817-PIP04-20)

AdoptedReference Number: EMA/441044/2020